Banfield, Christopher <br/><br/>
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.  [electronic resource] 

 -  Journal of clinical pharmacology  04 2018 
 - 434-447 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1552-4604 
<br/><br/><label>Standard No.: </label>10.1002/jcph.1046  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Biological Availability<br/>Blood Cell Count<br/>C-Reactive Protein--analysis<br/>Double-Blind Method<br/>Female<br/>Healthy Volunteers<br/>Humans<br/>Janus Kinase 1--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--administration & dosage<br/>Psoriasis--blood<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>TYK2 Kinase--antagonists & inhibitors<br/>Young Adult